Member Info for grizzlyb

Twitter.

Summary from Jason Comander: First 12 patients (cohorts 1 to 4 - advanced vision loss): No acuity improvements. Next 3 patients (cohort 5 - better baseline vision): 4 line gains in acuity. Next 3 patients (cohort 6 - better baseline than cohort 5): Treatment ongoing.

Aren't Edison paid by ReNeuron to provide these overviews? I'd expect them to be positive...

Awesome update.

It's not just as likely Monday is it?? If any new data, that would leave the whole weekend for it to be digested and published elsewhere before an RNS is issued.

Popes, Olav said they would update the market in the middle of the year and no news before then is good news. Jason Comander is presenting at today's summit, rather than ReNeuron. If he isn't presenting new data, then it follows that won't get an RNS. We will find out soon enough.

As ReNeuron's hRPC cells are gene independent, I wonder if, assuming continued positive efficacy, they would render Spark's Luxturna obsolete for RPE65 gene deficiency, if only because of the treatment price. An update tomorrow with longer term follow-up data is going to be significant, one way or another. Cohort 6 1st patient treated on 14th March, so there should be 40 days' data to present, plus updates from previous cohorts.

Whether an RNS at 0700 or an RNS out of hours, they'd both be before the summit, the only difference is that out of hours for the reason you've given could be construed as an intentional delay, therefore breaking AIM rules. If you're proposing we may get an RNS just before the summit presentation at 2145 UK time on Friday? Probably not. Dr. Jason Comander is presenting, so he'll only be able to convey results rather than a ReNeuron-specific update. Delaying a release is of no benefit to ReNeuron, and they seem quite on-board with releasing market-sensitive information in a timely manner since a small balls up a number of years ago. Regardless, a positive RNS will have a more immediate reach than a Friday afternoon summit presentation.

'An AIM company must issue notification without delay of any new developments which are not public knowledge which, if made public, would be likely to lead to a significant movement in the price of its AIM securities.' I'd suggest that releasing an RNS after trading hours but before the Summit starts would be an intentional delay. I also don't see any reason for doing it.

They can't save news for a summit. AIM rules dictate that material informtion must be disclosed to the market first, not to summit attendees.

It was, yes.

There was a 100-1 consolidation a while back - 1p became £1, but your share quantity became 100th of pre-consolidation quantity. So your 14p wouldn't be in profit until £14 was breached.

https://www.dailymail.co.uk/news/article-6919821/British-scientists-say-theyre-cusp-curing-blindness-stem-cell-treatment.html?ito=email_share_article-related

Prospero, if a large pharma started buying in sufficient quantity to be worthwhile, the price wouldn't have stayed remotely close to 60p. True value would be reflected quite rapidly.

No, it was for hRPC AND CTX, i.e. RP AND stroke.

To clarify, $425,000 is the per-eye treatment cost for Spark's Luxturna, not for ReNeuron's hRPC line. Analyst per-eye treatment costs for hRPC seem to have reduced from $50,000 (EU) to $100,000 (US/Japan), to $35,000 (EU) to $50,000 (US/Japan).

'ReNeuron will also receive tiered royalties at rates between 12% and 14% on SALES of the licensed products in the Chinese market.' What do you mean they don't need ReNeuron? You think they're going to steal ReNeuron's technology and halt royalty payments?

RP results look favourable so far compared to jCyte's jCell. Mean improvements: jCyte: +9 letters at 12 months ReNeuron: +16 letters at 2 months, 18 days and 18 days.

Jaytee, the other reason it dropped over the years is dilutive funding, and the fear of further dilution. That is either close to being a thing of the past, or all these positive updates are an effort to drive the price up prior to further dilution...

https://youtu.be/7poiamvo_FQ